ChemGenex completes SPP
Tuesday, 14 October, 2008
ChemGenex Pharmaceuticals [ASX: CXS] has completed its share placement program, raising over $13 million to fund the late-stage development of its omacetaxine candidate for chronic myeloid leukaemia.
15.3 million shares were placed during the program, trading at 85 cents each. During the period of the program, CXS shares traded at a high of 83 cents and a low of 72.5 cents.
All shares on offer were purchased. ChemGenex representatives said they were pleased the placement went so well considering the unstable global financial climate.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
